Surrey Heartlands

Joint Formulary & PAD

Bevacizumab gamma - Wet age-related macular degeneration

You are here : Home > Formulary Search > Bevacizumab gamma - Wet age-related macular degeneration

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravitreal injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
ICB
NICE
Restrictions / Comments :
Documents :
 
Guidelines (Local)
Wet Age-Related Macular Degeneration - Treatment Pathway -March 25 update
Evidence Review
Bevacizumab gamma in wet AMD- NICE briefing paper- January 2025
Webpage
NICE TA 1022 - Bevacizumab gamma for treating wet age-related macular degeneration

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Bevacizumab gamma
Indication :
Wet age-related macular degeneration
Group Name :
Keywords :
wet AMD, Ophthalmology, blindness, eyes, retinal, retina, NICE
Brand Names Include :
Lytenava
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Bevacizumab gamma is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Wet age-related macular degeneration.

Committee Recommendations (1)

01 Jan 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves bevacizumab gamma as a treatment option for the treatment of wet age-related macular degeneration as recommended by NICE TA1022

Bevacizumab gamma for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

Prescribing should be initiated and continued by a specialist clinician. If the patient has already been initiated on this medicine by a specialist clinician, please ensure this is recorded as a ‘Hospital Only Drug’ in the patient’s medication list, in order to be alert to potential side-effects and interactions with other medicines prescribed in primary care